---
title: Merck KGaA vs SK pharmteco
slug_a: merck-kgaa
slug_b: skpharmteco
site: cdmo
review_signal_gate: closed
canonical_path: /compare/merck-kgaa/skpharmteco
---

# Merck KGaA vs SK pharmteco

Side-by-side profile data from each company listing on this directory.

## Merck KGaA

- Profile: [/companies/merck-kgaa](/companies/merck-kgaa)

Merck KGaA — Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea.

Services: 0. Modalities: 0. Indications: 0. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in locations (1).

### Services

- Data not yet provided.

### Modalities

- Data not yet provided.

### Development capabilities

- Data not yet provided.

### Manufacturing capabilities

- Data not yet provided.

## SK pharmteco

- Profile: [/companies/skpharmteco](/companies/skpharmteco)

SK pharmteco — SK pharmteco is a CDMO offering comprehensive drug development and manufacturing services.

Services: 14. Modalities: 5. Indications: 0. Locations: 7. Certifications: 0. The strongest documented coverage currently appears in services (14).

### Services

- Small Molecule Development & Manufacturing
- API Synthesis & Manufacturing
- HPAPI Manufacturing (High-Potency)
- Flow Chemistry & Continuous Manufacturing
- ADC Payload & Linker Synthesis
- Viral Vector Manufacturing
- AAV Manufacturing
- Lentiviral Vector Manufacturing
- Peptide Manufacturing
- Process Development
- Technology Transfer
- CMC Analytical Development
- Quality Control Testing
- CMC Regulatory Submission Support

### Modalities

- Small Molecule
- Antibody-Drug Conjugate (ADC)
- Gene Therapy
- Peptide
- AAV / Viral Vector Platform

### Development capabilities

- Analytical method development
- Formulation development

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- HPAPI
- Flow Chemistry